Drug recall · October 25, 2023
Doxil (doxorubicin hydrochloride liposome injection) 50 mg in 25 mL recall
Why: CGMP Deviations: Product was exposed to temperatures exceeding the labeled storage conditions during transportation were released by mistake.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Doxil (doxorubicin hydrochloride liposome injection) 50 mg in 25 mL (2 mg/mL), Single-Dose Vial, Rx only, Manufactured for: Baxter Healthcare Corporation, Deerfield, IL 60015. NDC 0338-0067-01
- Lots / codes
Lot# MKZSU02, Exp 6/30/2024
- Quantity
- 472 vials
- Company
- Baxter Healthcare Corporation, Deerfield, IL
- Distribution
- Nationwide in the USA
- Initiated
- August 24, 2023 · Voluntary: Firm initiated
- Classified
- October 17, 2023
- Reported
- October 25, 2023
- Ended
- December 22, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Doxorubicin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.